Bristol-Myers Squibb Co.'s withdrawal of a high-profile US FDA filing for use of its PD-1 inhibitor Opdivo with its CTLA-4 inhibitor Yervoy in first-line non-small cell lung cancer based on the tumor mutational burden biomarker in the CheckMate 227 study puts more pressure on pipeline assets from the newly acquired Celgene Corp. to pay off.
Bristol said on Jan. 24, as part of its fourth-quarter/year-end 2018 earnings report, that it has voluntarily withdrawn the filing...






